Lee Ainslie’s Integra LifeSciences IART Stock Holding History

Lee Ainslie’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72,108	Closed	-$679K	–	240
2026 Q1	$679K	Buy	+72,108	New	+$792K	0.01%	195
2024 Q2	–	Sell	-9,419	Closed	-$334K	–	369
2024 Q1	$334K	Buy	9,419 +767	+9%	+$30.7K	0.01%	321
2023 Q4	$377K	Buy	8,652 +1,184	+16%	+$46.6K	0.01%	243
2023 Q3	$285K	Sell	7,468 -2,627	-26%	-$111K	0.01%	232
2023 Q2	$415K	Sell	10,095 -61	-0.6%	-$2.94K	0.01%	276
2023 Q1	$583K	Buy	10,156 +4,029	+66%	+$227K	0.01%	219
2022 Q4	$344K	Buy	+6,127	New	+$312K	0.01%	245
2021 Q4	–	Sell	-7,007	Closed	-$480K	–	470
2021 Q3	$480K	Sell	7,007 -15,292	-69%	-$1.08M	﹤0.01%	443
2021 Q2	$1.52M	Buy	22,299 +12,447	+126%	+$880K	0.01%	197
2021 Q1	$681K	Sell	9,852 -3,254	-25%	-$220K	0.01%	346
2020 Q4	$851K	Sell	13,106 -7,786	-37%	-$419K	0.01%	257
2020 Q3	$987K	Buy	+20,892	New	+$994K	0.02%	294

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Lee Ainslie's IART Position: Q2 2026 in Review

Lee Ainslie sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 72,108 shares — an estimated $679K sold.

Lee Ainslie first reported a position in IART in Q3 2020 and held it in 12 quarters. The position peaked at $1.52M in Q2 2021. 211 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Lee Ainslie reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
Lee Ainslie sold 72,108 Integra LifeSciences shares in Q2 2026, an estimated $679K.
Lee Ainslie first reported a position in Integra LifeSciences in Q3 2020 and held it in 12 quarters.
Lee Ainslie's Integra LifeSciences position peaked at $1.52M in Q2 2021.
211 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.